Entity Address, City or Town Entity Address, City or Town Fair Value Disclosures [Abstract] Description of operations policy. Description Of Operations Policy Policy [Text Block] Description of Operations Clinical development milestone. Clinical Development Milestones [Member] Clinical and Development Milestone [Member] Fair Value, Inputs, Level 1 [Member] Level 1 [Member] Schedule of Accrued Liabilities [Table Text Block] Schedule of Accrued and Other Current Liabilities Due from Related Parties, Current Prepaid expenses and other current assets from related parties Due from Related Parties, Current, Total Basis of presentation and principles of consolidation policy. Basis Of Presentation And Principles Of Consolidation Policy Policy [Text Block] Basis of Presentation and Principles of Consolidation Finance Lease, Liability, to be Paid, Year Three 2025 API shipment. A P I Shipment [Member] API Shipment [Member] Net Cash Provided by (Used in) Financing Activities [Abstract] Financing activities HiFiBiO agreement. Hi Fi Bi O Agreement [Member] HiFiBiO Agreement [Member] Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate Expected dividend yield Revenue resulting from changes to estimated variable consideration. Revenue Resulting from Changes to Estimated Variable Consideration Revenue resulting from changes to estimated variable consideration Astellas agreements. Astellas Collaboration Agreement [Member] Astellas Agreement [Member] Schedule of lease assets and related lease liabilities. Schedule Of Lease Assets And Related Lease Liabilities Table [Text Block] Schedule of Lease Assets and Related Lease Liabilities Amendment Flag Amendment Flag Bonds [Member] Agency bonds [Member] Operating Lease, Right-of-Use Asset Operating lease right-of-use assets Operating lease right-of-use assets, net Drug product revenue. Drug Product Revenue [Member] Drug Product Revenue [Member] Document Quarterly Report Document Quarterly Report Recently issued accounting guidance not yet adopted. Recently Issued Accounting Guidance Not Yet Adopted Policy [Text Block] Recently Issued Accounting Guidance Not Yet Adopted SEC Schedule, 12-09, Valuation Allowances and Reserves [Domain] SEC Schedule, 12-09, Valuation Allowances and Reserves Lessee, Operating Lease, Liability, Undiscounted Excess Amount Less: Interest Earnings Per Share, Policy [Policy Text Block] Net Income (Loss) per Share Net Loss per Share Equity Method Investments Ending balance Beginning balance Equity method investment in unconsolidated variable interest entity Equity method investments Repayments of Debt and Lease Obligation Repayments of lease obligations Statement [Table] Statement [Table] Operating Lease, Liability, Noncurrent Operating lease liabilities, non-current Operating lease liabilities Finance Lease, Liability, to be Paid, Year One 2023 Finance Lease, Interest Expense Interest on lease liabilities Operating Lease, Payments Operating cash flows from operating leases Cash payment related to lease Non cash right of use assets obtained in exchange for new lease liabilities. Non Cash Right Of Use Assets Obtained In Exchange For New Lease Liabilities [Abstract] Non-cash: Right-of-use assets obtained in exchange for new lease liabilities: Preferred Stock, Shares Outstanding Preferred stock, shares outstanding Preferred Stock, Shares Outstanding, Beginning Balance Preferred Stock, Shares Outstanding, Ending Balance Business Acquisition [Axis] Business Acquisition Revenue Recognition, Multiple-deliverable Arrangements [Line Items] Revenue Recognition, Multiple-deliverable Arrangements [Line Items] Commercial sales and other events milestone. Commercial Sales And Other Events Milestone Commercial sales and other events milestone Schedule of leases. Schedule Of Leases [Line Items] Schedule Of Leases [Line Items] Burdened manufacturing costs Manufacturing Costs Accrued API and bulk drug product price true-up current. Accrued API and bulk drug product price true-up current API and bulk drug product price true-up Collaborative arrangements license agreement and revenues. Collaborative Arrangements License Agreement And Revenues Policy [Text Block] Collaboration Agreements, License Agreement and Revenues Number of identified performance obligation at inception of agreement. Number Of Identified Performance Obligation At Inception Of Agreement Number of identified performance obligation at inception of agreement Product and Service [Axis] Product and Service Proceeds from sales of available for sale securities Proceeds From Sales Of Available For Sale Securities Proceeds from sales of available-for-sale securities Business Combination, Contingent Consideration, Liability Contingent consideration Business Combination, Contingent Consideration, Liability, Total Percentage of product manufacturing costs until manufacturing technology fully transferred. Percentage Of Product Manufacturing Costs Until Manufacturing Technology Fully Transferred Percentage of product manufacturing costs until manufacturing technology fully transferred Transfers of assets from level 2 to 1 Fair Value Assets Level2 To Level1 Transfer Amount Fair value assets level2 to level1 transfer amount. Employee-related Liabilities, Current Payroll and related accruals Employee-related Liabilities, Current, Total Intellectual Property Rights [Member] Intellectual Property [Member] Share-Based Payment Arrangement, Option [Member] Employee stock options [Member] Operating Lease, Weighted Average Remaining Lease Term Operating leases Liabilities and Equity Total liabilities, stockholders’ equity and non-controlling interests Cost, Product and Service [Extensible Enumeration] Cost, Product and Service [Extensible List] Collaborative arrangement aggregate consideration. Collaborative Arrangement Aggregate Consideration Aggregate considerations received Inventory, Raw Materials, Gross Raw materials Inventory, Raw Materials, Gross, Total Contract with customer liability deduction. Contract With Customer Liability Deduction Deduction Entity Incorporation, State or Country Code Entity Incorporation, State or Country Code Income Statement [Abstract] Repayments of finance lease liabilities. Repayments Of Finance Lease Liabilities Financing cash flows from finance leases Repayments of finance lease liabilities Finance Lease, Weighted Average Remaining Lease Term Finance leases Deferred Revenue, Total Deferred Revenue Deferred revenue Finance Lease, Liability, Current Finance lease liabilities, current Finance lease liabilities Finance lease liabilities, current Liabilities, Current Total current liabilities Contract liabilities, Contract Liabilities [Member] Contract Liabilities [Member] Increase (decrease) in operating lease liabilities, current. Increase Decrease In Operating Lease Liabilities Current Operating lease liabilities, current Lessee, Operating Lease, Liability, to be Paid, Year Three 2025 Due to related parties deferred revenue noncurrent. Due To Related Parties Deferred Revenue Noncurrent Deferred revenue non-current to related party Business Acquisition, Acquiree [Domain] Business Acquisition, Acquiree Fair Value, Recurring [Member] Fair Value, Measurements, Recurring [Member] Interest Expense Interest expense Interest Expense, Total Accounts Receivable, Allowance for Credit Loss Reductions to gross accounts receivable Accounts Receivable, Allowance for Credit Loss, Beginning Balance Accounts Receivable, Allowance for Credit Loss, Ending Balance Development and other revenue. Development And Other Revenue [Member] Development and Other Revenue [Member] Development Revenue [Member] Represents the long-term portion of the outstanding principal and accrued interest of advances in the form note agreements received by the entity to fund various product development efforts. Accrued Product Development Costs Product development obligations Finance lease accumulated amortization. Finance Lease Accumulated Amortization Accumulated amortization Increase (Decrease) in Contract with Customer, Liability Deferred revenue US Treasury and Government [Member] U.S. government bonds [Member] Long-Term Purchase Commitment, Category of Item Purchased [Domain] Long-term Purchase Commitment, Category of Item Purchased Preferred Stock, Shares Authorized Preferred stock, shares authorized Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table] Schedule Of Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Table] Operating Lease, Weighted Average Discount Rate, Percent Operating leases Entity Small Business Entity Small Business Number of Reportable Segments Number of reportable segment Collaborative Arrangement and Arrangement Other than Collaborative [Axis] Collaborative Arrangement and Arrangement Other than Collaborative Investments [Domain] Investments Accounting Standards Update 2019-01 [Member] ASC 842 [Member] Assets, Current Total current assets Contract with Customer, Contract Asset, Contract Liability, and Receivable [Table Text Block] Roll-forward of Related Contract Liabilities Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year 2022 (remaining nine month period) Description of sales return. Description Of Sales Return Description of sales return Variable Interest Entity Disclosure [Text Block] Variable Interest Entity Weighted average number of common shares used to calculate net loss per share - basic Weighted Average Number of Shares Outstanding, Basic Weighted Average Number of Shares Outstanding, Basic, Total Finance Lease, Liability Finance lease liability Present value of lease liabilities Finance Lease, Liability, Total City Area Code City Area Code Lessee, operating lease, expiration period. Lessee Operating Lease Expiration Period Lessee, operating lease, expiration period Geographic Distribution, Foreign [Member] Foreign subsidiaries [Member] The amount of additional consideration based on net sales of product as defined under a collaboration agreement. Additional Consideration Based On Net Sales Additional consideration based on net sales description Schedule of share based payment award stock options and employee stock purchase plan valuation assumptions. Schedule Of Share Based Payment Award Stock Options And Employee Stock Purchase Plan Valuation Assumptions Table [Text Block] Schedule of Assumptions used to Estimate Fair Value of Stock Options Granted and Purchases under 2014 Employee Share Purchase Plan Deferred Revenue, by Arrangement, Disclosure [Table Text Block] Summary of Amounts Recognized as Revenue Share-Based Payment Arrangement [Abstract] Foreign Government Debt [Member] Foreign government bonds [Member] Property taxes and other current. Property Taxes And Other Current Property taxes and other taxes Liabilities Total liabilities Document Period End Date Document Period End Date Revenue from multiple-deliverable arrangements that include licensing fees and services revenue and the amount of consideration recognized during the period for milestones. Licensing revenue is consideration received from another party for the right to use, but not own, certain of the entity's intangible assets. Licensing arrangements include, but are not limited to, rights to use a patent, copyright, technology, manufacturing process, software or trademark. Licensing fees are generally, but not always, fixed as to amount and not dependent upon the revenue generated by the licensing party. An entity may receive licensing fees for licenses that also generate royalty payments to the entity. Services revenue may be derived by providing other, non-specified, services during the reporting period. License Fees And Milestones Revenue License and milestone revenue from a related party Lease Contractual Term [Domain] Lease Contractual Term Asset-Backed Securities [Member] Asset-backed securities [Member] Upfront payment. Initial Upfront Payment Initial upfront payment Miscellaneous receivables. Miscellaneous Receivables Miscellaneous receivables Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset Transfers Into Level 3 Transfers of assets into level 3 Percentage of pre-launch inventory capitalized of aggregate inventory balance. Percentage Of Pre Launch Inventory Capitalized Of Aggregate Inventory Balance Percentage of pre-launch inventory capitalized of aggregate inventory balance Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value Weighted average estimated fair value Percentage increases on anniversary of rent commencement date option two. Percentage Increases On Anniversary Of Rent Commencement Date Option Two Percentage increases on each anniversary of rent commencement date 2028 Debt Securities, Available-for-Sale, Amortized Cost Amortized Cost Amortized Cost Deferred revenue, net of current ($49,2733 and $25,891 to a related party) Contract with Customer, Liability, Noncurrent Statistical Measurement [Axis] Statistical Measurement Accounts Payable, Related Parties, Current Accounts payable to related party Equity Method Investments [Table Text Block] Summary of Equity Method Investment Subsequent Event [Line Items] Interest Income, Other Interest income Stockholders' Equity Attributable to Noncontrolling Interest Non-controlling interests Stockholders' Equity Attributable to Noncontrolling Interest, Total Stockholders' Equity Attributable to Noncontrolling Interest, Beginning Balance Stockholders' Equity Attributable to Noncontrolling Interest, Ending Balance Finance Lease, Interest Payment on Liability Operating cash flows from finance leases Related Party [Axis] Related Party Assets Total assets Operating Costs and Expenses [Abstract] Operating costs and expenses: Commercial milestone. Commercial Milestone Commercial milestone Revenue, Performance Obligation, Description of Payment Terms Description of payment term Long-term Debt, Excluding Current Maturities, Total Long-Term Debt, Excluding Current Maturities Long-term debt, less current portion Net loss per share - diluted Earnings Per Share, Diluted Earnings Per Share, Diluted, Total Beijing Kangda Yongfu Pharmaceutical Co., LTD. Beijing Kangda Yongfu Pharmaceutical Co L T D [Member] Beijing Kangda Yongfu Pharmaceutical Co., LTD [Member] Cash and Cash Equivalents [Abstract] Entity Address, Postal Zip Code Entity Address, Postal Zip Code Maximum additional future option, clinical, regulatory, and commercial milestone payments. Maximum Additional Future Option Clinical Regulatory And Commercial Milestone Payments Maximum additional future option, clinical, regulatory, and commercial milestone payments Document Fiscal Period Focus Document Fiscal Period Focus Increase (Decrease) in Accounts Receivable Accounts receivable, net Preferred stock, $0.01 par value; 125,000 shares authorized; no shares issued and outstanding at June 30, 2022 and December 31, 2021 Preferred Stock, Value, Issued Preferred Stock, Value, Issued, Total Preferred Stock, Value, Issued, Beginning Balance Preferred Stock, Value, Issued, Ending Balance APIC, Share-Based Payment Arrangement, Increase for Cost Recognition Stock-based compensation APIC, Share-based Payment Arrangement, Increase for Cost Recognition, Total Contract With Customer Liability [Table] Contract With Customer Liability [Table] Contract With Customer Liability [Table] United states and rest of world. United States And Rest Of World [Member] U.S./RoW [Member] Beijing economic-technological development area. Beijing Economic Technological Development Area [Member] Beijing Economic-Technological Development Area [Member] Operating Lease, Liability Operating lease liability Present value of lease liabilities Operating Lease, Liability, Total Net cash provided by (used in) financing activities Net Cash Provided by (Used in) Financing Activities Represents the total amount of non-contingent, non-refundable, upfront payments included under the collaborative agreement as arrangement consideration. Proceeds From Upfront Non Contingent Non Refundable And Time Based Payments Upfront, non-contingent, non-refundable and time-based payments Contract with customer liability net of balance presented against contract asset. Contract with customer liability net of balance presented against contract asset Balance Presented Net Against Contract Asset Statement of Financial Position [Abstract] Entity File Number Entity File Number Net transfer price. Net Transfer Price [Member] Net Transfer Price [Member] Discounts and rebates. Discounts And Rebates [Member] Discounts and Rebates [Member] Finance Lease, Liability, to be Paid Total future lease payments Statement of Cash Flows [Abstract] Sublease Income Sublease income Proceeds from Sale, Maturity and Collection of Investments Proceeds from maturities of investments Proceeds from Sale, Maturity and Collection of Investments, Total Schedule of Investments [Abstract] Co development information sharing and committee services. Co Development Information Sharing And Committee Services [Member] Co-development, information sharing & committee services [Member] Schedule of maturities of finance and operating leases liabilities. Schedule Of Maturities Of Finance And Operating Leases Liabilities Table [Text Block] Schedule of Maturities of Finance and Operating Leases Liabilities SEC Schedule, 12-09, Valuation Allowances and Reserves Type [Axis] SEC Schedule, 12-09, Valuation Allowances and Reserves Type Geographical [Domain] Geographical Statistical Measurement [Domain] Statistical Measurement Statement of Stockholders' Equity [Abstract] Commitments and contingencies. Commitments And Contingencies [Line Items] Commitments And Contingencies [Line Items] Sales Returns and Allowances [Member] Sales Returns [Member] Lease, Cost [Table Text Block] Components of Lease Expense Equity Method Investment, Ownership Percentage Ownership Percentage Subsequent Events [Abstract] Fair Value Disclosures [Text Block] Fair Value Measurements Accounting Standards Update 2014-09 [Member] ASC 606 [Member] Proceeds from Issuance of Common Stock Proceeds from issuance of common stock Lease obligations non-current. Lease Obligations Non-Current Long-term portion of lease obligations Reduction of other expenses Reduction of Other Expenses Reduction of other expenses. Preferred Stock, Par or Stated Value Per Share Preferred stock, par value Deferred revenue ($5,204 and $3,201 to related parties) Deferred Revenue Profit share liability Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain, before Tax Gross Unrealized Holding Gains Lessee, Lease, Description [Line Items] Lessee Lease Description [Line Items] Due to related parties deferred revenue current. Due To Related Parties Deferred Revenue Current Deferred revenue current to related party Drug product revenue from related party. Drug Product Revenue From Related Party Drug product revenue from a related party Deferred approval milestone. Deferred Approval Milestone [Member] Deferred Approval Milestone [Member] Supplemental Balance Sheet Disclosures [Text Block] Balance Sheet Components AstraZeneca AB. AstraZenecaAB [Member] Astra Zeneca [Member] Subsequent Event Subsequent Events [Text Block] Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] Recently issued and adopted accounting guidance. Recently Issued And Adopted Accounting Guidance Policy [Text Block] Recently Issued and Adopted Accounting Guidance Weighted average number of common shares used to calculate net loss per share - diluted Weighted Average Number of Shares Outstanding, Diluted Weighted Average Number of Shares Outstanding, Diluted, Total Finite-Lived Intangible Assets, Major Class Name [Domain] Finite-Lived Intangible Assets, Major Class Name Research and Development Arrangement, Contract to Perform for Others, Type [Domain] Research and Development Arrangement, Contract to Perform for Others, Type Commercial Paper [Member] Commercial paper [Member] Finance lease and operating lease assets. Finance Lease And Operating Lease Assets Total lease assets Astellas agreement. Astellas Agreement [Member] Astellas Agreement [Member] Current Fiscal Year End Date Current Fiscal Year End Date Investment Type [Axis] Investment Type Equity method investment increase (decrease) from currency translation. Equity Method Investment Increase Decrease From Currency Translation Currency Translation Manufacture and supply of pamrevlumab. Manufacture And Supply Of Pamrevlumab [Member] Manufacture and Supply of Pamrevlumab [Member] Depreciation Depreciation Depreciation, Total Commitments and contingencies. Commitments And Contingencies [Table] Commitments And Contingencies [Table] Increase (decrease) in operating lease right-of-use assets. Increase Decrease In Operating Lease Right Of Use Assets Operating lease right-of-use assets Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations Total cash and cash equivalents at end of period Total cash and cash equivalents at beginning of period Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations, Total Other Assets, Noncurrent Other assets Other Assets, Noncurrent, Total Represents the amount of milestone payments related to commercial sales under the collaborative agreement. Commercial Sales Milestone Commercial sales milestone Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest Balance Balance Total equity Entity Address, Address Line One Entity Address, Address Line One Noncontrolling Interest [Member] Noncontrolling Interests [Member] Transaction Type [Axis] Transaction Type Finite-Lived Intangible Assets by Major Class [Axis] Finite-Lived Intangible Assets by Major Class Accrued Liabilities, Current [Abstract] The total cash consideration received under a collaboration agreement that has been allocated to the different significant units of accounting and includes the portion that has been deferred for revenue recognition. Cash Consideration Received Under Collaboration Agreement Total Consideration Royalty Revenue [Member] Royalty [Member] Provision for (benefit from) income taxes Income Tax Expense (Benefit) Provision for income taxes Income Tax Expense (Benefit), Total Deferred for future recognition. Deferred For Future Recognition [Member] Constrained for Future Recognition [Member] Finance Lease, Liability, to be Paid [Abstract] Finance Leases Income Tax Disclosure [Text Block] Income Taxes Preferred Stock, Shares Issued Preferred stock, shares issued Preferred Stock, Shares Issued, Total Balance Sheet Location [Domain] Balance Sheet Location Other Accrued Liabilities, Current Other Payments to Acquire Property, Plant, and Equipment Purchases of property and equipment Payments to Acquire Property, Plant, and Equipment, Total Income Tax Disclosure [Abstract] Disaggregation of Revenue [Abstract] Collaborative Arrangement [Member] Collaborative Arrangement [Member] Regulatory milestone. Regulatory Milestones [Member] Regulatory Milestone [Member] Acquisition and variable interest entity abstract. Acquisition And Variable Interest Entity [Abstract] China performance obligation. China Performance Obligation [Member] China performance obligation [Member] Costs and Expenses Total operating costs and expenses Fair Value Hierarchy and NAV [Axis] Level 1 [Member] Share-Based Payment Arrangement [Policy Text Block] Stock-Based Compensation Accounts Receivable, Related Parties, Current Accounts receivable from related parties Finance Lease, Liability, to be Paid, Year Four 2026 Schedule of leases. Schedule Of Leases [Table] Schedule Of Leases [Table] Contract with Customer, Liability, Revenue Recognized Recognized as Revenue Accrued co-promotion expenses - current. Accrued Co Promotion Expenses Current Accrued co-promotion expenses - current Lessee, Finance Lease, Option to Extend Lessee, finance lease, option to extend Increase (Decrease) in Other Noncurrent Liabilities Other long-term liabilities Operating Income (Loss) Loss from operations Cornea products. Cornea Products [Member] Cornea Products [Member] Related Party [Domain] Related Party Collaborative Arrangement and Arrangement Other than Collaborative [Table] Schedule Of Collaborative Arrangements And Noncollaborative Arrangement Transactions [Table] Research and Development in Process Expense for acquired in-process research and development asset Accrued Professional Fees, Current Professional services Accrued and other current liabilities ($43,286 and $4 to a related party) Accrued Liabilities and Other Liabilities Accrued Liabilities and Other Liabilities, Total Debt Securities, Available-for-sale, Realized Gain (Loss), Excluding Other-than-temporary Impairment, Total Debt Securities, Available-for-Sale, Realized Gain (Loss), Excluding Other-than-temporary Impairment Realized loss on sales of available-for-sale securities Realized loss on sales of available-for-sale securities Entity Filer Category Entity Filer Category Geographic Distribution [Axis] Geographic Distribution Percentage increases on each anniversary of rent commencement date. Percentage Increases On Each Anniversary Of Rent Commencement Date Percentage increases on each anniversary of rent commencement date 2023 Money Market Funds, at Carrying Value Money market funds Product revenue policy. Product Revenue Policy Policy [Text Block] Product Revenue, Net Drug product revenue. Drug Product Revenue Policy [Text Block] Drug Product Revenue Payments to Acquire in Process Research and Development Payment made for acquired in-process research and development asset Entity Current Reporting Status Entity Current Reporting Status Represents the potential amount of milestone payments related to development and regulatory approval under the collaborative agreement. Development And Regulatory Approval Milestones Development and regulatory approval milestones Profit share. Profit Share [Member] Profit Share [Member] Inventory, Net Inventories Total inventories Stockholders' Equity Attributable to Parent Total stockholders’ equity Stockholders' Equity Attributable to Parent, Beginning Balance Stockholders' Equity Attributable to Parent, Ending Balance AOCI Attributable to Parent [Member] Accumulated Other Comprehensive Income (Loss) [Member] Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations Effect of exchange rate change on cash and cash equivalents Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations, Total Schedule of Available-for-Sale Securities Reconciliation [Table Text Block] Summary of Amortized Cost, Gross Unrealized Holding Gains or Losses, and Fair Value of Investments Entity Tax Identification Number Entity Tax Identification Number Income Statement Location [Axis] Income Statement Location Common stock, $0.01 par value; 225,000 shares authorized at June 30, 2022 and December 31, 2021; 93,733 and 92,881 shares issued and outstanding at June 30, 2022 and December 31, 2021 Common Stock, Value, Issued Common Stock, Value, Issued, Total Common Stock, Value, Issued, Beginning Balance Common Stock, Value, Issued, Ending Balance Retained Earnings (Accumulated Deficit) Accumulated deficit Retained Earnings (Accumulated Deficit), Total Retained Earnings (Accumulated Deficit), Beginning Balance Retained Earnings (Accumulated Deficit), Ending Balance OCI, Debt Securities, Available-for-Sale, Gain (Loss), after Adjustment and Tax Change in unrealized gain or loss on investments OCI, Debt Securities, Available-for-Sale, Gain (Loss), after Adjustment and Tax, Total Equity Components [Axis] Equity Components Shares issued from stock plans net of payroll taxes paid shares. Shares Issued From Stock Plans Net Of Payroll Taxes Paid Shares Shares issued from stock plans, net of payroll taxes paid, Shares Long term investment excluding equity method investments. Long Term Investment Excluding Equity Method Investments Long-term investments Accounting Standards Update [Domain] Accounting Standards Update Represents the total potential amount of milestone payments related to development, regulatory approval and commercial sales under the collaborative agreement. Potential Milestones Potential milestone payments Shorenstein properties LLC. Shorenstein Properties L L C [Member] Shorenstein Properties LLC [Member] Leases [Abstract] Balance at June 30, 2022 Contract with Customer, Liability Deferred Revenue Deferred revenue Deferred revenues from associated contracts Contract with Customer, Liability, Total Balance at December 31, 2021 Disaggregation of Revenue [Table] Disaggregation Of Revenue [Table] Accrued contract liabilities to pharmaceutical distributors current. Accrued Contract Liabilities To Pharmaceutical Distributors Current Contract liabilities to pharmaceutical distributors Entity Emerging Growth Company Entity Emerging Growth Company Represents the amount of fixed and determinable non-contingent upfront payments included under the collaborative agreement as arrangement consideration. Proceeds From Upfront Non Contingent And Time Based Payments Upfront, non-contingent and time-based payments received Maximum future milestone payments. Maximum Future Milestone Payments Maximum future milestone payments Cost of Revenue Cost of goods sold Cost of Revenue, Total Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term Expected term (in years) Transaction [Domain] Transaction Europe [Member] Europe [Member] Lessee, Operating Lease, Liability, to be Paid [Abstract] Operating Leases Revenue recognized from co-development services, manufacturing of clinical supplies, committee services and information services and other revenue. Collaboration Services And Other Revenue Collaboration services and other revenue from a related party Selling and Marketing Expense, Total Selling and Marketing Expense Sales and marketing Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Maximum Expected volatility, maximum Document Transition Report Document Transition Report Assets, Fair Value Disclosure, Total Assets, Fair Value Disclosure Total fair value of financial assets Astra Zeneca agreements. Astra Zeneca Agreements [Member] AstraZeneca Agreements [Member] Nonoperating Income (Expense) Interest income and other income (expenses), net Interest income and other income (expenses), net Scheduled rent commencement year option two. Scheduled Rent Commencement Year Option Two Rent increase commencement year second option Commitments and Contingencies Disclosure [Text Block] Commitments and Contingencies Accumulated Other Comprehensive Income (Loss), Net of Tax Accumulated other comprehensive loss Accumulated Other Comprehensive Income (Loss), Net of Tax, Total Accounts receivable, net ($26,779 and $10,930 from related parties) Accounts Receivable, after Allowance for Credit Loss, Current Accounts Receivable, after Allowance for Credit Loss, Current, Total Entity Common Stock, Shares Outstanding Entity Common Stock Shares Outstanding Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to pre-clinical and clinical trial activities, including those performed by third parties. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). Accrued Preclinical And Clinical Trial Current Preclinical and clinical trial accruals Other comprehensive gain (loss), net of taxes Other Comprehensive Income (Loss), Net of Tax Net Income (Loss) Attributable to Parent Net income (loss) Net loss Net loss Operating Lease, Liability, Current Operating lease liabilities, current Operating lease liabilities Lease amendment. Lease Amendment [Member] Lease Amendment [Member] Unrealized loss (gain) on equity investments. Unrealized Loss Gain On Equity Investments Unrealized loss on equity investments Additional Paid-in Capital [Member] Additional Paid-in Capital [Member] Collaborative Arrangement and Arrangement Other than Collaborative [Domain] Collaborative Arrangement and Arrangement Other than Collaborative Collaborative arrangement aggregate consideration for milestone and upfront payments. Collaborative Arrangement Aggregate Consideration For Milestone And Upfront Payments Aggregate consideration received for milestone and upfront payments Unbilled upfront payment Contract with customer liability. Contract With Customer Liability [Line Items] Contract with Customer Liability [Line Items] Payment, Tax Withholding, Share-Based Payment Arrangement Cash paid for payroll taxes on restricted stock unit releases Entity Registrant Name Entity Registrant Name Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax Foreign currency translation adjustments Foreign currency translation adjustments Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax, Total Cash and Cash Equivalents, at Carrying Value Cash and cash equivalents Total cash and cash equivalents Cash and Cash Equivalents, at Carrying Value, Beginning Balance Cash and Cash Equivalents, at Carrying Value, Ending Balance Lessee, Lease, Description [Table] Lessee Lease Description [Table] Share-Based Payment Arrangement, Noncash Expense Stock-based compensation Share-based Payment Arrangement, Noncash Expense, Total Number of optional rights to extend lease. Number Of Optional Rights To Extend Lease Optional rights to extend lease Statement of Comprehensive Income [Abstract] Property, Plant and Equipment, Net Property and equipment, net Property and equipment, net Property, Plant and Equipment, Net, Beginning Balance Property, Plant and Equipment, Net, Ending Balance Lessee, finance lease, expiration period. Lessee Finance Lease Expiration Period Lessee, finance lease, expiration period Finance Lease, Right-of-Use Asset, Amortization Amortization of finance lease right-of-use assets Amortization of right-of-use assets Award Type [Domain] Award Type Statement [Line Items] Statement [Line Items] Schedule of lease term and discount rate. Schedule Of Lease Term And Discount Rate Table [Text Block] Schedule of Lease Term and Discount Rate Title of 12(b) Security Title of 12(b) Security Increase (Decrease) in Accounts Payable Accounts payable Increase (Decrease) in Accounts Payable, Total Agency bonds. Agency Bonds [Member] Agency bonds [Member] Increase (decrease) in operating lease liabilities, non-current. Increase Decrease In Operating Lease Liabilities Non Current Operating lease liabilities, non-current Common Stock [Member] Common Stock [Member] Accounting policy. Accounting Policy [Line Items] Accounting Policy [Line Items] Net Cash Provided by (Used in) Operating Activities [Abstract] Operating activities Equity Component [Domain] Equity Component Purchases of available-for-sale securities Payments to Acquire Debt Securities, Available-for-Sale Purchases of available-for-sale securities Finance Lease, Liability, to be Paid, Remainder of Fiscal Year 2022 (remaining nine month period) Revenue from Contract with Customer, Excluding Assessed Tax Total revenue Revenue from Contract with Customer, Excluding Assessed Tax, Total Drug product revenue recognized Finance Lease, Liability, Undiscounted Excess Amount Less: Interest Schedule of Cash and Cash Equivalents [Table Text Block] Schedule of Cash and Cash Equivalents Entity Address, State or Province Entity Address, State or Province Variable Interest Entity, Qualitative or Quantitative Information, Ownership Percentage Percentage of outstanding shares owned Contractual Obligation Outstanding non-cancelable purchase obligations Contractual Obligation, Total Lessee, Operating Lease, Liability, to be Paid, Year Four 2026 Geographical [Axis] Geographical Acquisition and variable interest entity table. Acquisition And Variable Interest Entity [Table] Acquisition And Variable Interest Entity [Table] Gross accounts receivable. Gross Accounts Receivable [Member] Gross Accounts Receivable [Member] Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect Net increase (decrease) in cash and cash equivalents Document Type Document Type Falikang. Falikang [Member] Falikang [Member] E U supply and Astellas agreement. E U Supply And Astellas Agreement [Member] UNITED STATES U.S. [Member] Entity Shell Company Entity Shell Company Rebates and discounts. Rebates And Discounts [Member] Rebates and Discounts [Member] Increase (Decrease) in Inventories Inventories Increase (Decrease) in Inventories, Total Share-Based Payment Arrangement, Expense Total stock-based compensation expense Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items] Fair Value, Recurring and Nonrecurring [Table] Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Table] Corporate Bond Securities [Member] Corporate bonds [Member] Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest [Abstract] Stockholders’ equity: Security Exchange Name Security Exchange Name Revenue from Contract with Customer [Abstract] Revenue: Finance Lease, Liability, Noncurrent Finance lease liabilities, non-current Finance lease liabilities Finance lease liabilities, non-current Significant Accounting Policies [Text Block] Significant Accounting Policies Net Cash Provided by (Used in) Operating Activities Net cash used in operating activities Contract with customer milestone method. Contract With Customer Milestone Method Table [Text Block] Summary of License Revenue and Development Revenue Recognized under Agreement Other Comprehensive Income (Loss), Net of Tax [Abstract] Other comprehensive income (loss): Commitments and Contingencies Disclosure [Abstract] Operating Lease, Cost Operating lease cost Adjustments to additional paid in capital shares issued from stock plans net of payroll taxes paid. Adjustments To Additional Paid In Capital Shares Issued From Stock Plans Net Of Payroll Taxes Paid Shares issued from stock plans, net of payroll taxes paid Future manufacturing clinical regulatory and commercial milestone payments. Future Manufacturing Clinical Regulatory And Commercial Milestone Payments Future manufacturing clinical regulatory and commercial milestone payments Finance Lease, Liability, to be Paid, Year Two 2024 Finance lease liability payments due after year four. Finance Lease Liability Payments Due After Year Four Beyond 2026 Common Stock, Shares, Outstanding Common stock, shares outstanding Common Stock, Shares, Outstanding, Beginning Balance Common Stock, Shares, Outstanding, Ending Balance Inventory, Work in Process, Gross Work-in-progress Accretion (Amortization) of Discounts and Premiums, Investments Net accretion of premium and discount on investments Fair Value, Inputs, Level 2 [Member] Level 2 [Member] Direct sales. Direct Sales [Member] Direct Sales [Member] Debt Securities, Available-for-Sale Fair Value Fair Value Investments Net Cash Provided by (Used in) Investing Activities [Abstract] Investing activities Commitments and Contingencies Commitments and Contingencies Common Stock, Shares, Issued Common stock, shares issued Common Stock, Shares, Issued, Total Acquisition and variable interest entity line items. Acquisition And Variable Interest Entity [Line Items] Acquisition And Variable Interest Entity [Line Items] Due to Related Parties, Current Accrued and other current liabilities to related party Accrued liabilities to related party Due to Related Parties, Current, Total Beijing Falikang Pharmaceutical Co. Ltd. Beijing Falikang Pharmaceutical Co Ltd [Member] Beijing Falikang Pharmaceutical Co Ltd Beijing Falikang Pharmaceutical Co. Ltd [Member] Minimum [Member] Minimum [Member] CHINA China [Member] Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum Risk-free interest rate, maximum Accounting Standards Update [Axis] Accounting Standards Update Accrued Liabilities, Current Total accrued and other current liabilities Schedule of Available-for-Sale Securities [Table] Schedule Of Available For Sale Securities [Table] Research and pre-clinical stage development programs. Research And Pre Clinical Stage Development Programs [Member] Research and Pre-Clinical Stage Development Programs [Member] Restricted Cash and Cash Equivalents, Noncurrent Restricted time deposits Restricted Cash and Cash Equivalents, Noncurrent, Total Lessee, finance lease, option to extend the additional lease term. Lessee Finance Lease Option To Extend Additional Lease Term Lessee, finance lease, option to extend the additional lease term Supplies, net. Supplies Net Net unbilled co-development revenue Net unbilled contract assets Amount of aggregate consideration receivable under collaborative arrangement excluding drug product revenue. Collaborative Arrangement Aggregate Consideration Excluding Drug Product Revenue Aggregate consideration received excluding drug product revenue Bond and mutual funds. Bond And Mutual Funds [Member] Bond and mutual funds [Member] Product [Member] Product Revenue, Net [Member] Product [Member] Award Type [Axis] Award Type Other Nonoperating Income (Expense), Total Other Nonoperating Income (Expense) Other Nonoperating Income (Expense) [Abstract] Interest and other, net Represents the total amount of non-contingent, non-refundable, upfront payments included under the collaborative agreement as arrangement consideration. Proceeds From Upfront Non Contingent And Non Refundable Payments Proceeds from upfront, non-contingent and non-refundable payments Research and Development Expense Research and development Research and Development Expense, Total Lessee, Operating Lease, Liability, to be Paid Total future lease payments Lessee, Finance Lease, Term of Contract Lessee, finance lease, initial lease term Lessee, Operating Lease, Term of Contract Lessee, operating lease, lease term Finance lease and operating lease liability. Finance Lease And Operating Lease Liability Total lease liabilities Entity Central Index Key Entity Central Index Key Lessee, Finance Lease, Existence of Option to Extend [true false] Lessee, finance lease, existence of option to extend Variable consideration payment received from estimated future co-development billing. Variable Consideration Payment Received From Estimated Future Co Development Billing Remainder of transaction price, variable consideration from estimated future co-development billing Transaction price, variable consideration from estimated future co-development billing Short-Term Investments Short-term investments Short-term Investments, Total Right-of-Use Asset Obtained in Exchange for Finance Lease Liability Finance leases Accounting Policies [Abstract] Revenue gross transfer price from contract with customer excluding assessed tax. Revenue Gross Transfer Price From Contract With Customer Excluding Assessed Tax Gross transfer price Reduction of accrued and other current liabilities Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities Accrued and other liabilities Collaborative arrangements license agreement and revenues. Collaborative Arrangements License Agreement And Revenues Disclosure [Text Block] Collaboration Agreements, License Agreement and Revenues Debt Securities, Available-for-Sale [Line Items] Schedule of Available-for-sale Securities [Line Items] Disaggregation of Revenue [Line Items] Disaggregation Of Revenue [Line Items] Finance Lease, Right-of-Use Asset, after Accumulated Amortization Finance lease right-of-use assets Finance lease right-of-use assets, net Finance lease right-of-use assets Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate Expected volatility Finance Lease, Weighted Average Discount Rate, Percent Finance leases Commercial Paper, at Carrying Value Commercial paper Measurement Frequency [Axis] Measurement Frequency Share-Based Payment Arrangement [Text Block] Stock-Based Compensation Transaction price allocated to performance obligations. Transaction Price Allocated To Performance Obligations Transaction price and allocated to performance obligations Subsequent Event [Table] General and Administrative Expense, Total General and Administrative Expense General and administrative Organization, Consolidation and Presentation of Financial Statements [Abstract] Research and Development Expense [Member] Research and development [Member] Reduction of other assets Increase (Decrease) in Other Current Assets Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum Risk-free interest rate, minimum Lease, Cost Total lease cost Right-of-Use Asset Obtained in Exchange for Operating Lease Liability Operating leases Equity Method Investment, Nonconsolidated Investee [Domain] Equity Method Investment, Nonconsolidated Investee Increase in deferred revenue. Increase In Deferred Revenue [Member] Increase in Deferred Revenue [Member] Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract] Adjustments to reconcile net loss to net cash used in operating activities: Retained Earnings [Member] Accumulated Deficit [Member] Total amount of revenue recognized for license and development services under the collaboration agreement as of a given date. Cumulative Revenue License And Development Revenue Recognized Cumulative Revenue Billed Contracts Receivable Schedule of supplemental cash flow information related to leases. Schedule Of Supplemental Cash Flow Information Related To Leases Table [Text Block] Schedule of Supplemental Cash Flow Information Related to Leases Investment income in unconsolidated variable interest entity Income (Loss) from Equity Method Investments Income (Loss) from Equity Method Investments, Total Share of Net Income Investment income (loss) Money Market Funds [Member] Money market funds [Member] Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items] Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items] Geographic Distribution [Domain] Geographic Distribution Weighted-average discount rate. Weighted Average Discount Rate [Abstract] Weighted-average discount rate: Research and Development Arrangement, Contract to Perform for Others, Type [Axis] Research and Development Arrangement, Contract to Perform for Others, Type Additional Paid in Capital Additional paid-in capital Additional Paid in Capital, Total Additional Paid in Capital, Beginning Balance Additional Paid in Capital, Ending Balance Entity Interactive Data Current Entity Interactive Data Current Profit share percent. Profit Share Percent Profit share percent Related Party Transactions Disclosure [Text Block] Related Party Transactions Acquired in process research and development asset. Acquired In Process Research And Development Asset Acquired in-process research and development asset Revenue Recognition, Multiple-deliverable Arrangements [Table] Revenue Recognition Multiple Deliverable Arrangements [Table] Represents the percentage of costs that will be funded by the other party under a collaborative agreement for development costs. Percentage Of Funding For Costs Percentage of joint development costs committed to fund Related Party Transactions [Abstract] Lessee, Operating Lease, Liability, to be Paid, Year One 2023 Contract with customer liability additions. Contract With Customer Liability Additions Additions Loss Contingency, New Claims Filed, Number Putative securities class action complaints filed License [Member] License Revenue [Member] License [Member] Local Phone Number Local Phone Number Fair Value, Assets Measured on Recurring Basis [Table Text Block] Fair Values of Financial Assets Measured on Recurring Basis Schedule of Earnings Per Share, Basic and Diluted [Table Text Block] Summary of Reconciliation of Basic and Diluted Net Income (Loss) Per Share Calculation Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] Share Based Compensation Arrangement By Share Based Payment Award [Line Items] Lease Contractual Term [Axis] Lease Contractual Term United States/Rest of World and China. United States Rest Of World And China [Member] U.S./RoW and China [Member] License agreement with Eluminex. License Agreement With Eluminex [Member] Eluminex [Member] Transfers of assets from level 1 to 2 Fair Value Assets Level1 To Level2 Transfer Amount Fair value assets level1 to level2 transfer amount. Disaggregation of Revenue [Table Text Block] Transaction Price Related to Consideration Received and Accounts Receivable Allocated to Performance Obligations along with Associated Deferred Revenue and Product Revenue Net Category of Item Purchased [Axis] Category of Item Purchased Other Liabilities, Noncurrent Other long-term liabilities Total other long-term liabilities JAPAN Japan [Member] Income Statement Location [Domain] Income Statement Location Finance lease, right-of-use assets - cost. Finance Lease Right Of Use Assets Cost Right-of-use assets cost Selling, General and Administrative Expenses [Member] Selling, general and administrative [Member] OCI, Debt Securities, Available-for-Sale, Gain (Loss), after Adjustment and Tax [Abstract] Available-for-sale investments: Shares, Outstanding Balance, Shares Balance, Shares Increase (Decrease) in Prepaid Expense and Other Assets Prepaid expenses and other current assets Increase (Decrease) in Prepaid Expense and Other Assets, Total Risks and uncertainties. Risks And Uncertainties Policy [Text Block] Risks and Uncertainties Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table] Schedule Of Share Based Compensation Arrangements By Share Based Payment Award [Table] Astellas. Astellas [Member] Astellas [Member] Document Fiscal Year Focus Document Fiscal Year Focus Lessee, Operating Lease, Liability, to be Paid, Year Two 2024 Net loss per share - basic Earnings Per Share, Basic Earnings Per Share, Basic, Total Assets [Abstract] Assets U.S. government bonds. U S Government Bonds [Member] U.S. government bonds [Member] Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Minimum Expected volatility, minimum Prepaid Expense and Other Assets, Current Total prepaid expenses and other current assets Prepaid expenses and other current assets Share-Based Payment Arrangement [Member] 2014 Employee Share Purchase Plan [Member] Interest Income (Expense), Nonoperating, Net Total interest and other, net Schedule of drug product revenue. Schedule Of Drug Product Revenue Table [Text Block] Schedule of Drug Product Revenue Business Acquisition, Percentage of Voting Interests Acquired Percentage of outstanding shares acquired Operating lease, right-of-use assets - cost. Operating Lease Right Of Use Assets Cost Right-of-use assets cost Liabilities and Equity [Abstract] Liabilities, stockholders’ equity and non-controlling interests Net Income (Loss), Including Portion Attributable to Noncontrolling Interest Net loss Net Income (Loss), Including Portion Attributable to Noncontrolling Interest, Total Assets, Current [Abstract] Current assets: Revenue gross from contract with customer excluding assessed tax. Revenue Gross From Contract With Customer Excluding Assessed Tax Gross revenue FibroGen Beijing. Fibro Gen Beijing [Member] FibroGen Beijing [Member] Revenue from Related Parties Revenue related to collaboration agreements Contract with customer, liability, increase (decrease) from current translation and other. Contract With Customer Liability Increase Decrease From Current Translation And Other Currency Translation and Other Fair Value Hierarchy and NAV [Domain] Fair Value Hierarchy and NAV Measurement Frequency [Domain] Measurement Frequency Increase (Decrease) in Operating Capital [Abstract] Changes in operating assets and liabilities: Related Party Transaction [Line Items] Related Party Transaction [Line Items] Lease, Cost [Abstract] Finance lease cost: Product revenue from a related party. Product Revenue Product revenue from a related party Income (Loss) from Continuing Operations before Equity Method Investments, Income Taxes, Noncontrolling Interest Loss before income taxes Loss before income taxes Cover [Abstract] Other-than-temporary Impairment Loss, Debt Securities, Available-for-sale, Total Other-than-temporary impairment loss Other-than-temporary Impairment Loss, Debt Securities, Available-for-sale Product and Service [Domain] Product and Service Inventory, Finished Goods, Gross Finished goods Inventory, Finished Goods, Gross, Total Liabilities, Current [Abstract] Current liabilities: Maximum [Member] Maximum [Member] Unrealized gain (loss) on investments, net of tax effect OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, after Tax Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block] Schedule of Recorded Stock-Based Compensation Expense Accrued profit share current. Accrued Profit Share Current Roxadustat profit share to AstraZeneca Net Cash Provided by (Used in) Investing Activities Net cash provided by (used in) investing activities Current portion of lease financing obligations. Current portion of lease financing obligations Schedule of Inventory, Current [Table Text Block] Schedule of Inventory Fair Value, Inputs, Level 3 [Member] Level 3 [Member] Use of Estimates, Policy [Policy Text Block] Use of Estimates Lessee, finance lease, additional lease expiration period. Lessee Finance Lease Additional Lease Expiration Period Lessee, finance lease, additional lease expiration period Lessee operating lease liability payments due after year four. Lessee Operating Lease Liability Payments Due After Year Four Beyond 2026 Cash Cash Cash, Beginning Balance Cash, Ending Balance Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Transfers out of Level 3 Transfers of assets out of level 3 Bulk drug product. Bulk Drug Product [Member] Manufacture and Supply of Roxadustat. Manufacture And Supply Of Roxadustat [Member] Manufacture and Supply of Roxadustat [Member] Rent commencement year option one. Scheduled Rent Commencement Year Option One Rent increase commencement year first option Investment income in unconsolidated variable interest entity Investment (gain) loss in unconsolidated variable interest entity. Investment Gain Loss In Unconsolidated Variable Interest Entity Leases. Leases Common Stock, Shares Authorized Common stock, shares authorized Operating lease, accumulated amortization. Operating Lease Accumulated Amortization Accumulated amortization Trading Symbol Trading Symbol Equity Securities [Member] Equity investments [Member] Cash paid for amounts included in the measurement of lease liabilities. Cash Paid For Amounts Included In Measurement Of Lease Liabilities [Abstract] Cash paid for amounts included in the measurement of lease liabilities: Increase (decrease) in accrued interest for finance lease liabilities. Increase Decrease In Accrued Interest For Finance Lease Liabilities Accrued interest for finance lease liabilities Selling, General and Administrative Expense Selling, general and administrative Selling, General and Administrative Expense, Total Accounting policy. Accounting Policy [Table] Accounting Policy [Table] Represents the maximum contractual maturity period for available-for-sale securities. Available For Sale Securities Contractual Maturity Period Contractual maturities of available-for-sale investments Balance Sheet Location [Axis] Balance Sheet Location Comprehensive Income (Loss), Net of Tax, Attributable to Parent Comprehensive loss Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate Risk-free interest rate Proceeds from Sale of Property, Plant, and Equipment, Total Proceeds from Sale of Property, Plant, and Equipment Proceeds from sale of property and equipment Accounts Payable, Current Accounts Payable, Current, Total Accounts payable Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax Gross Unrealized Holding Losses Gross Unrealized Holding Losses Increase (Decrease) in Other Operating Assets Other assets Increase (Decrease) in Other Operating Assets, Total Other Purchases. Other Purchases [Member] Other Purchases [Member] Contract with Customer, Liability, Change in Timeframe, Performance Obligation Satisfied, Revenue Recognized Changes in revenue from changes to estimated variable consideration Schedule of Related Party Transactions, by Related Party [Table] Schedule Of Related Party Transactions By Related Party [Table] Equity Method Investment, Nonconsolidated Investee [Axis] Equity Method Investment, Nonconsolidated Investee Common Stock, Par or Stated Value Per Share Common stock, par value (Gain) / loss on disposal of property and equipment Gain (Loss) on Disposition of Property Plant Equipment, Excluding Oil and Gas Property and Timber Property Contract with customer liability reclassified to accrued liability. Contract With Customer Liability Reclassified to Accrued Liability Reclassified to Accrued Liability Sales to Falikang. Sales To Falikang [Member] Sales To Falikang [Member] Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount Anti-dilutive shares outstanding Cash and Cash Equivalents, Fair Value Disclosure Assets fair value disclosure Weighted-average remaining lease term. Weighted Average Remaining Lease Term [Abstract] Weighted-average remaining lease term (years):